Literature DB >> 33607693

Successful Regression in Patients with Progressive Keratoconus by Corneal Crosslinking.

Tobias Röck1, Eva-Maria Konrad1, Daniel Röck1, Matthias Bramkamp2, Gunnar Blumenstock3, Karl Ulrich Bartz-Schmidt1.   

Abstract

BACKGROUND: Since 2019, corneal collagen crosslinking (CXL) is included in the catalog of procedures covered by statutory health insurance in Germany. CXL is an established ophthalmological procedure for the last 20 years. The aim of this investigation was the measurement of progression before and after CXL. MATERIAL UND
METHODS: 65 consecutive eyes with progressive keratoconus from 53 patients were included in the retrospective study, which were observed at the University Eye Hospital Tübingen at least two years before and at least two years after CXL. The time of observation took place from October 2009 until March 2018. Parameters of interest had been the best corrected visual acuity (BCVA) and the keratometric values from the elevation maps measured by a Scheimpflug camera.
RESULTS: 65 eyes of 53 patients had been documented. The study population included 46 (86.8%) male and 7 (13.2%) female subjects. The mean age was 24 ± 8 years. The averaged observation time between the primary consultation and CXL showed 25 ± 15 months. Preoperatively the mean BCVA pointed out in a significant increase (0.13 ± 0.17 [first visit] vs. 0.23 ± 0.22 [preOP], p < 0.0001) while the mean Kmax resulted in a statistically significant increase (46.34 ± 3.33 dpt [first visit] vs. 48.78 ± 4.17 dpt [preOP], p < 0.0001). The mean thinnest point of the cornea showed a significant decrease (490.48 ± 34.23 µm [first visit] vs. 468.62 ± 29.84 µm [preop], p < 0.0001). Postoperatively the mean BCVA resulted in a significant improvement at the 12th postoperative month in comparison to the preoperative measurement (0.23 ± 0.22 [preOP] vs. 0.16 ± 0.14 [12 months], p = 0.04 respectively 0.17 ± 0.17 [24 months], p = 0.0006). The mean Kmax demonstrated in the 12th postoperative month a significant reduction (48.78 ± 4.17 dpt [preOP] vs. 47.91 ± 3.41 dpt [12 months], p = 0.0009 respectively 48 ± 4.56 dpt [24 months], p = 0.0051). The mean thinnest point of the cornea indicated a decrease at the 12th postoperative month (468.62 ± 29.84 µm [preOP] vs. 459.82 ± 35.88 µm [12 months], p = 0.0078 respectively 453.47 ± 43.39 µm [24 months], p = 0.0227).
CONCLUSION: CXL is a successful procedure for the therapy of progressive keratoconus. Thieme. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33607693     DOI: 10.1055/a-1264-7928

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  2 in total

1.  Corneal cross-linking in patients with keratoconus: up to 13 years of follow-up.

Authors:  Christian Enders; Diana Vogel; Jens Dreyhaupt; Waltraud Wolf; Aylin Garip-Kuebler; Jonathan Hall; Lukas Neuhann; Jens Ulrich Werner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-10-05       Impact factor: 3.535

2.  Impact of keratoconus stage on outcome after corneal crosslinking.

Authors:  Caroline Julia Gassel; Daniel Röck; Eva-Maria Konrad; Gunnar Blumenstock; Karl Ulrich Bartz-Schmidt; Tobias Röck
Journal:  BMC Ophthalmol       Date:  2022-05-06       Impact factor: 2.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.